Meta-Analysis of two drugs in the Treatment for Community-Acquired Pneumonia
Abstract
Objective To compare the effects and safety of moxifloxacin and levofloxacin in the treatment for communityacquired pneumonia( CAP) in China. Methods The data of random controlled trials( RCTs) about moxifloxacin and levofloxacin on CAP were analyzed by Meta-analysis method to evaluate the clinical efficacy,bacteriological efficacy and incidence of adverse reaction. Results 11 RCTs were included into this study. Meta-analysis showed that the two groups had significant differences in clinical efficacy( Z = 6. 21,P 0. 01,OR = 2. 91,95% CI 2. 07- 4. 07) and bacteriological efficacy( Z = 4. 91,P 0. 01,OR = 2. 97,95% CI 1. 92- 4. 58). While,the incidences of adverse reaction between the the groups were similar( Z = 0. 71,P = 0. 48,OR = 0. 86,95% CI 0. 56- 1. 31). No significant publication bias was found by Begg's test and Egger's test. Conclusion The effects were higher in Chinese CAP patients treated by moxifloxacin than levofloxacin. But the safety was similar.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.